October 30, 2007
McLean Hospital and Harvard Medical School researcher will discuss clinical study at SupplySide West in Las Vegas.
(New York, NY) October 30, 2007 – A study by Deborah Yurgelun-Todd, Ph.D. applying two complementary imaging methods, magnetic resonance spectroscopy (MRS) and functional magnetic resonance imaging (fMRI), to document the effects of Cognizin™ Citicoline on the human brain in healthy volunteers were recently completed at McLean Hospital, an affiliate of Harvard Medical School. Dr. Yurgelun-Todd will give an overview of her findings at SupplySide West as part of the Kyowa Hakko USA sponsored VendorWorks, Thursday, November 8, 10 -10:50 a.m. in the Murano Room at the Sands Convention Center.
Dr. Yurgelun-Todd, director of the Cognitive Neuroimaging and Neuropsychology Laboratories at the McLean Hospital Brain Imaging Center and associate professor of Psychiatry at Harvard Medical School, found the study indicated that after six weeks of Cognizin™ use, energy stores within the brain were increased. The clinical study using neuroimaging data also showed increased concentration, focus and improved accuracy, better performance and improved speed on cognitive tasks.
Dr. Yurgelun-Todd is an innovative leader in applying neurophysiological and cognitive methods to evaluate neurobiological changes associated with brain maturation, pharmacotherapy, neuropsychiatric disorders and substance abuse. Her research focus is on identifying the neuropsychological and neurobiological bases of risk factors for major psychiatric disorders including schizophrenia and bipolar disorder.
Cognizin™ Citicoline is the premier branded ingredient manufactured by Kyowa Hakko USA, one of the world leaders in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. The company has developed a proprietary fermentation production technique for the exclusive development of Cognizin™.
Citicoline has been used extensively for the promotion of optimal neural and cognitive function. Citicoline (Cytidine 5’- diphosphocholine also known as CDP Choline) is involved in the synthesis of phospholipids, which make up the membranes of cells, especially the pathway involving phosphatidylcholine. When taken orally, Citicoline is metabolized to yield the free nucleotide uridine and choline. Peak plasma levels occur several hours after consumption for delivery to various parts of the body. Both elements cross the blood-brain barrier, become incorporated into brain membrane phospholipids and increase the production of neurotransmitters in the central nervous system, including the synthesis of acetylcholine, noradrenaline and dopamine.
# # # #
You May Also Like
Expo East celebrated innovations, ideas that help the industry growSep 29, 2023
Vision 2030: Insights from Today’s State of Natural You Can UseSep 29, 2023
Notable trends a New Hope editor captured at Expo EastSep 28, 2023
CPG veterans launch equity investment firm for purpose-driven brandsSep 28, 2023